- The Company was Incorporated at Mumbai.
- The Company acquired a plot of land from MIDC at Patalganga in
Kulaba district of Maharashtra State about 55 kms. from Mumbai.
- 18,773 Bonus equity shares issued in proportion 1:1.
- The name of the Company was changed from The Chemical Industrial &
Pharmaceutical Laboratories Ltd., to the present one with effect from
- 37,546 Bonus equity shares issued in proportion 1:1 in January
- During August, the Company obtained the consent of the Controller
of Capital Issues to issue 3,00,000-15% secured non-convertible
redeemable debentures of Rs 100 each aggregating to Rs 300 lakhs by
private placement. The entire issue was subscribed by public
institutions. They are redeemable at a premium of 5% during 1993-94.
- The Company launched several new products viz., Asthalin and
Beclate Rotahalers/Rotacaps-dry powder inhalation devices for asthma,
presolar capsules - the first synergistic combination of a beta
blocker and a sustained release calcium channel blocker for
hypertension, Restyl tablets - the first anxiolytic-cum-anti
depressant, Theo-Asthalin SR
tablets - the first sustained release combination of two widely used
bronchodilators, bromolin dry syrup and bromolin-250 capsules -
antibiotic-cum-mucolytic agents, dilgard tablets - a new calcium
channel blocker for angina, ibugesic plus suspension - a non
anti inflammatory and anti-pyretic analgesic for paediatric use.
- 75,092 Bonus equity shares issued in proportion 1:1.
- The latest drugs introduced during the year were (i) Ciplox tablets
(250 & 500 mg.) and infusion (50 and 100 ml.), a broad spectrum
fluoroquinolone antibacterial for severe infections, (ii) cefadur
capsules (250 & 500 mg.) and syrup (30 ml.), a cephalosporin
antibiotic, (iii) Ulcimax tablets (20 & 40 mg.), a long-acting H2
antogonist for peptic ulcers and (iv) theoped syrup, a paediatric
bronchodilator. Sales in the Company's `PROTEC' division exceeded Rs
5.50 crores for the second year of its operations.
- The Company launched several new products viz., Aerocort inhaler,
an anti-inflammatory bronchodilator, Norflox eye/ear drops - a broad
spectrum fluoroquinolone antibacterial, Pirox Gel - the first topical
piroxicam formulation in the country, Cofenac tablets - an
anti-infammatory analgesic, Kinetal 400 tablets - a multi-functional
drug for vascular insufficiency, Novaclox Ped tablets - a dispensible
combination antibiotics, Terfed tablets and Suspension - a new
non-sedative antihistamine, Depryl tablets - a broad - spectrum
antidepressant, Asthalin Respirator Solution - a bronchodilator for
pressure ventilation in acute asthma. The Company spent Rs 4.22
crores on R&D and Rs 8.09 crores on modernisation and expansion of
plant and machinery.
- The new products launched during the year were lomac capsules - a
new antiulcerant, cromal inhaler - the first optimum - dose inhalant
prophylactic for asthma, ciplox eye drops - the total bactericide for
ocular infections, etosid injection - the first injection of
indigenously manufactured etoposide for cancer therapy, proflox
tablets - a key fluoroquinolone antibiotic and vasopril tablets - an
ACE inhibitor for long-term management of hypertension. The research
development win g of the Company developed during the y ar felodipine
- the latest anti-hypertensive drug, selegilinje - a new bulk drug for
the treatment of Parkinson's disease, cetirizine HCI - an
anti-histamine drug and nimodipine - a cerebral vasodilator. Work
the anti-AIDS drug AZT reached an advance stage of development. The
research and development wing also developed anthelmintics
oxfendazole and oribendazole, two veterinary products for exports.
- In May, 6,000 equity shares offered at par as rights to pref.
shareholders in prop. 1:1. Only 5,216 shares taken up. Allotment of
5 equity shares pending.
- Some of the new products introduded were Zidovir capsules an
antiretroviral for HIV injection, Cipril tablets for hypertension,
Optipres eyedrops for glaucoma patients, Felogard for hypertension,
Nodine, a non-narcotic analgesic, etc.
- In compliance with the provisions of the Companies Act, 1956, the
Company redeemed its 6,000 preference shares of Rs 100 each as on
- Pref. shares redeemed on 30.9.92, 1,55,395 bonus equity shares
issued in prop. 1:1.
- New products introduced were - Beclate Aquanase - a major
advancement in allergic rhinitis; Cytoplatin - an anticancer agent;
Forcan - an antifungal; Imusporin - an immunosuppressant in organ
transplantation; Kelfer - an iron chelator for thalassaemia; Lanzol -
a proton pump
inhibitor; Nuzac - an antidepresant; Odirox - a macrolide antibiotic
and Qinarsol - for chloroquin-resistant malaria.
- Equity shares subdivided 155,39,500. Equity shares allotted shares
issued in prop. 1:5.
- The Company's manufacturing unit at Kurkumbh, which was
commissioned in April. The second phase of expansion of the location
was under way and this was to provide specialised facilities for the
manufacture of new chemical entites.
- Effective 4th July, the Company was forced to declare a lock-out as
some of the workmen at the Vikhroli Unit resorted to indiscipline.
The Company initiated steps to mitigate the impact it could have on
- New products introduced were - Acivir - antivirus herpes, Anlopres
- antivirus herpes, Anlopres - Calcium channel blocker in
hypertension and angina, Anlopres AT - a combination
antihypertensive, Budecort 200 - a higher strength corticosterord in
bronchial asthma, Budenase AQ - a corticosteroid protection in
allergic rhinitis, cronal - a nast cell
stabiliser in allerg ic conjunctivitis, cytonid - a antiandrogenic
agent in prostate cancer, Norflox - an antidiarrhoeal in diarrhoea of
mixed origin, optipes S - betaxocol eye drops, profenac -
anti-inflammatory eye drops, Terfed D - a combination antihistamine
Trivedon 20 - used in ischaemic heart disease.
- A new chemical entity, candocuronium iodide - a neuromuscular
blocking agent was manufactured, other new bulk drugs manufactured
include: Acyelovir - antiviral, Amlodipine besylate -
antihypertensive and antianginal, Febantel - veterinary anthelmintic,
antiandrogen, Flutivcasone dipropionate - a corticosteriod,
zenprolide acetate - GMRH analogue.
- 13,43,383 rights equity shares issued (Prem. Rs. 60/-). However,
the Rights issue was underwritten.
- The products launched during the year were Azee (azithromycin
capsules) - a new macrolide antibiotic; Budecort (budesonide
rotacaps) - dry powder inhaled corticosteriod therapy for asthama;
Cipril H (lisionopril + hydrochlorothiazide tablets) - a combination
antihypertensive; Ciplox TZ (ciprofloxacin + tinidazole tablets) -
the combination bactericide for aerobic/anaerobic infections; Entosec
(secnidazole tablets) - single dose therapy for
amoebiasis/trichomoniasis; Fincar (fin asterid tablets) - for beign
prostatic hyperphasia; Metolar (metaprolol injection) - beta-blocker
protection for post myocardial infarction & Zoflut (fluticasone
propionate cream) - a new topical corticosteroid.
- The products introduced during the year were; Alerid-D - an
antihistamine and decongestant for cold and congestion, Amlopres L -
a tablet for hypertension, Apuatears - an eye drop, Azee 1000 - a
single dose for STDs, Budecort Respules - neubulised corticosteroid
for asthma, Dilgard XL - a diltiazem, Glumet - tablet for obese
diabetics, Glygard - tablet for abese diabetics, Glygard - tablet for
diabetics, Ipranase AQ (ipratropium nasal spray) - an anticholinergic
therapy for rhinorrhoea, Ocutim (an eye drop) - a glaucoma therapy
acquafilm formulation, Osteifos 10 - tablet for osteoporosis, Prolyte
Fizz - a rehydration effervescent tablet, Pylokit - an advanced H
pylori kit, Risnia - an a typical antipsychotic, Stavir - an
antiretroviral for AIDS, Synclar 250 - an advanced macrolide
antibiotic, Theoday - a tablet for asthma, Zoflut Lotion - a topical
- The bulk division of the Company had taken up, the development and
manufacture of some new drugs viz., budesonide - antiasthmatic
corticosteroid, carvedilol - alpha/beta blocker, ebastine -
antihistamine, formoterol fumarate - antiasthmatic, meloxicam - for
osteroarthritis and rheumatoid arthritis, moclobemide -
antidepressant, mometasome furoate - antiflammatory corticosteroid,
pantorazole sodium sesquihydrate - antiulcerant, sildenafil citrate -
- The Company has developed a form-fill-seal equipment for the first
time in India, for the manufacture of sterile formulations. This was
commissioned at Vikhroli factory and is working to its full capacity.
Additional capacities were set up at Kurkumbh for manufacture of
effervescent tablets, soft gel capsules and injectable formulations.
The Company has incurred a capital expenditure of Rs 22.73 crores
during the year.
- The Rs. 3.69 billion Cipla has finalised a marketing joint venture
with Australia-based Genpharm, as part of its strategy to consolidate
its global presence.
- Pharmaceutical major Cipla Ltd grabbed the attention of traders at
the Mumbai Stock Exchange (BSE) on December 26 after a large block of
about 75,000 shares of the company valued at little over Rs 5 crore
- The Rs.369-crore Cipla Ltd has entered into a souring arrangement
with US-based Geneva Pharmaceuticals, a wholly-owned subsidiary of
Swiss multinational Ciba, for a range of generic drugs.
- Pharmaceutical companies, Cipla and Wockhardt, will be seeking
shareholders' approval for a proposed share buyback at their
forthcoming annual general meetings.
- In a notice to shareholders, Cipla has proposed introduction of a
new article, Article 64 A, in the Articles of Association of the
company to enable the company to purchase and re-issue any of its
shares. The existing Article 64 prohibits the company from buying
its own shares
and applying any of its funds for the purchase of any shares of the
- The share price of Cipla Ltd, the leading pharmaceutical company
scaled a new peak of Rs 920 on the Mumbai Stock Exchange on Sept 29
following fresh bull charge. The scrip opened at Rs 900 and shot up
to Rs 920 during mid-session and closed at Rs 884 following hectic
- Ranbaxy and Cipla, have entered into a strategic partnership to
jointly market a select basket of drugs. The alliance will bring
forth their strengths in the strongly emerging cardiovascular and
perennial anti-infectives market.
- As a first step, the two molecules being jointly launched are
Carvedilol, a new generation anti-hypertensive and Cefpodoxime
Proxetil, an advanced third generation oral cephalosporin.
- The Rs 541-crore Cipla has forged a strategic alliance with the
UK-based Neolab for marketing a range of generic drugs. The
alliance, while improving the Indian company's access to the
European market for off-patent drugs, will also see Cipla rake in
royalties on sales of products covered under the deal.
- Cipla's latest tie-up in the international market comes close on
the heels of the company's strategic partnership with the Delhi-based
Ranbaxy Laboratories for a select basket of drugs.
- The Mumbai-based Cipla is working on abbreviated new drug
applications (ANDAs) in collaboration with international generics
firms for a range of products like flutamide (for advanced prostatic
cancer) and felodipine, for hypertension.
- Cipla and Ranbaxy Laboratories have expanded an existing
partnership by adding one more new drug in their co-marketing
- Cipla has tied up with the US-based Zenith Goldline and United
Research Labs for marketing Flutamide, an oncology drug, and
Felodipine, a cardiovascular drug, in the US and European markets.
- Domestic pharma giant, Cipla, has despatched its first free
consignment of anti-AIDS drug, ‘Nevirapine’, to the Indian Government
for distribution under the public health system.
-Reduces the price of its anti-HIV medicines such as Stavir, Lamivir,
Nevimune, Dinex, Indivan, Triomune, Efavir and Duovir
-Revokes interim dividend of Rs 5 per share on face value of Rs 10
per share for FY 2001-02
-Company included in the World Health Organisation's (WHO's) list of
-Chairman and Managing Director YK Hamied was presented with the
lifetime contribution award for excellence in the pharmaceutical
industry by Union chemicals & fertilisers minister SS Dhindsa
-Resigns from Indian Pharmaceutical Alliance (IPA) over Patents Bill
-Applies its requisiton for Abbreviated New Drug Application (ANDA)
with US regulators for a post-menopausal drug
-National Pharmaceutical Pricing Authority (NPPA) issues notices to
Cipla along with Ranbaxy for overcharging the products
-Completes research studies on three Anti-HIV Drugs
-Registers Stavudine, Nevirapine, other anti-AIDS products in South
-Signs long-term agreement with Morton Grove Pharmaceuticals Inc
(MGP) of Illinois, US, for product launch in the US market
-Avesthagen forges alliance with Cipla
-Cipla has joined a global initiative taken up by the Vatican in
collaboration with global generic pharmaceutical manufacturers and
the International Federation of Catholic Pharmacies and Academics to
-Cipla join hands with Pentech Pharma
-Indian pharma major Cipla, a pioneer in supplying cheap generic AIDS
drugs in Africa, has patented its three-in-one combination tablet
Triomune in South Africa
-Cipla introduces 'Duova' to fight chronic obstructive pulmonary
- Launches a new treatment for arthritis in technical collaboration
with California-based Cymbiotics Inc.
-Set-up state-of-the-art facility for manufacture of formulations at
Baddi, Himachal Pradesh.
-Cipla introduces new drug for arthritis
-Cipla to sign deal with Akorn Inc for anti-infective drug
-Cipla to produce generic versin of bird-flu drug
-Cipla to join hands with Roche
- Cipla introduces new drug for arthritis
- Cipla receives Scrip Award for Best Company in an Emerging Market
-Safe & steady strategy gives Cipla lead over Ranbaxy
-Cipla sets up subsidiary in Dubai
-Cipla ties up with Ivax for US market
-Cipla receives tentative US FDA approval for AIDS drugs
-Cipla receives Pharma Excellence Award for 'Sustained Growth'
-Cipla has given the Bonus in the Ratio of 3:2
- Cipla unveils anti-malaria global initiative.
-Set-up state-of-the-art facility for manufacture of formulations at
-Award for the Forbes Asia's Best Under A Billion List!
-Cipla’s drug included in US anti-AIDS initiative
-Anti-AIDS blitz sees pharma firms locked in ugly battle
-Cipla launches emergency contraception tablet
-Cipla launches estradiol transdermal spray in India
-Cipla launches cut-price zanamivir in India
-Cipla receives International Trade Awards 2006 for outstanding
exporter of the year (Pharmaceuticals, Healthcare and Life Sciences
-Cipla Ltd has appointed Mr. Pankaj Patel as a Director in casual
vacancy with effect from
March 05, 2008.
-Cipla launched Roche's generic version of anti-infection drug
-Cipla wins Erlotinib case against Roche
-Pharmaceuticals Export Promotion Council Awards
-Cipla launches drug to treat Swine flu virus
-Cipla wins patent fight against Gilead Sciences
-Cipla Ltd acquired Meditab Specialities Pvt. Ltd. (Meditab) for an
aggregate consideration of Rs. 133.35 crores.
-Cipla Medpro has signed a deal with Biomab, a division of Chinese
company Desano Pharma.
-Cipla sold the marketing rights of i-Pill to Piramal Healthcare for
Rs 95 crore in cash.
-Cipla has tied up with the Manipal Group-promoted 'Stempeutics
- Drug Maker Cipla has launched the generic Version of Pirfenidone,
used to treat Idiopathic Pulmonary Fibrosis, a progressive Lung
disease.India is the 2nd market to have this drug after Japan.
-Cipla Cancer Palliative Care Centre launched 24 hour helpline to
offer counselling to ensure more people use of the free services
-Cipla India's second largest drug firm, has agreed to acquire South
African Drugmaker Cipla Medpro with 51% stake amounts to 0
-Cipla bags tentative approval for HIV treatment tablets
-Drug giant Cipla Ltd has announced price reduction on 3 major
anti-cancer drugs including Erlotinib (ERLOCIP), Docetaxel (DOCETAX)
and Capecitabine (CAPEGARD).
-Cipla bags award in the Field of Export of Pharmaceuticals during
the year conferred the Highest Award 'Platinum'.
-Cipla announces an offer to the shareholders of Medpro for 100%
-Cipla launches the first Biosimilar of Etanercept in India
-Cipla wins USD 188.95 million of Global Fund ARV Tender
-MMV announces collaborations with Cipla and Strides
-Cipla licenses rights for innovative product
- Cipla, S&D Pharma collaborate to enter Czech Republic and Slovakia
-Cipla collaborates with Hetero to launch its second biosimilar drug
-Cipla invests in Chase Pharmaceuticals to support Alzheimer’s
disease drug development
-The Registered Office of the Company has been shifted from Mumbai
Central, Mumbai - 400008 to Cipla House, Peninsula Business Park,
Ganpatrao Kadam Marg, Lower Parel, Mumbai - 400 013, Tel:
022-24826000 / 022-2482695,1Fax: 022-24826893.